REGENXBIO Inc. cash flow to debt ratio of -47.58% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

REGENXBIO Inc.'s free cash flow has increased -28.02% from $-175.56M last year to $-126.38M, signaling increasing performance

REGENXBIO Inc.'s debt to equity ratio is 3.49, which means that the company's assets are unhealthy financed, signaling financial risk.

REGENXBIO Inc.'s debt has increased relative to shareholder equity from 0.32 last year to 3.49 today, signaling weakened financials

REGENXBIO Inc. has negative EBITDA, making leverage ratio unreliable

REGENXBIO Inc.'s interest coverage ratio is -3.91, which means that the company struggles to meet interest obligations, signaling financial risk.

REGENXBIO Inc.'s profit margin has increased (-58.69%) in the last year from -272.54% to -112.58%, signaling increasing performance

REGENXBIO Inc.'s short-term assets of $281.28M exceed its short-term liabilities of $118.09M

REGENXBIO Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

REGENXBIO Inc.'s return on equity of -220.07%, is lower than 15.00%, indicating bad performance

REGENXBIO Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

REGENXBIO Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

REGENXBIO Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

REGENXBIO Inc. has negative free cash flow, indicating cash burn

REGENXBIO Inc.'s yearly earnings has increased -14.63% since last year from $-227.10M to $-193.88M, signaling increasing performance

REGENXBIO Inc.'s yearly revenue has increased 104.54% since last year from $83.33M to $170.44M, signaling increasing performance

ROIC -48.55% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

REGENXBIO Inc.'s 3-year revenue CAGR of 14.78% is positive, indicating growing revenue over the past 3 years

REGENXBIO Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

REGENXBIO Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

REGENXBIO Inc. has insufficient data to evaluate this check.

REGENXBIO Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

REGENXBIO Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

REGENXBIO Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

REGENXBIO Inc. is overvalued relative to its fair value price of -75.80 based on Earnings Fair Value model

REGENXBIO Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

REGENXBIO Inc. has a price-to-book ratio of 7.67x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

REGENXBIO Inc. has a price-to-sales ratio of 3.15x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue